After acute paricalcitol supplementation, there is a significant reduction in plasmatic and urinary NGAL values and in IL-17, IL-6, IL-1β, TNF-α, and IFN-γ levels in CKD patients; values return to a normal range. This evidence concerns the gene IL1B and chronic kidney disease.